Transitional cell carcinoma in a Herniated vesical diverticulum

Carcinoma in vesical diverticula is a rare clinical entity and rarer still is the herniation of the vesical diverticulum into the scrotal sac. Carcinoma arising within a vesical diverticulum often represents a diagnostic as well as a therapeutic challenge, with overall poor outcome despite all available forms of treatment. Multidetector CT helps in the diagnosis and detailed evaluation of carcinoma arising from the vesical diverticulum by allowing excellent reconstructions in any desired plane. We report here a case of transitional cell carcinoma arising in a herniated vesical diverticulum with hepatic metastasis

Metabolic properties of lactobacilli in women experiencing recurring episodes of bacterial vaginosis with vaginal pH≥5

While 60% of women experiencing recurring episodes of bacterial vaginosis (BV) with vaginal pH≥5 are depleted of resident probiotic lactobacilli, the remainder carry one or more strains of lactobacilli. Their ability to make D-lactic acid is, however, low (3.94±0.72 mM/L) compared to the D-lactic acid produced by strains from healthy vagina with vaginal pH~4 (8.04±1.07 mM/L) culture supernatant of 0.5 McFarland concentration (P<0.001)

Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system.

Contains fulltext : 65629.pdf ( ) (Open Access

Centchroman Regresses Mastalgia: A Randomized Comparison with Danazol

We conducted a randomized trial to evaluate effectiveness of Centchroman in control of mastalgia and compared it with Danazol. Research Question- Is proportion of pain relief achieved by Centchroman similar to or inferior to that achieved by Danazol? In a randomized controlled trial of Centchroman vs. Danazol in mastalgia, 81 patients with mastalgia were studied. Thirty-nine patients were randomized to Danazol arm and 42 in Centchroman arm. The treatment was given for 12 weeks, followed by observation for 12 weeks. The pain was measured by visual analogue scale (VAS) of 0–10. At 12 weeks 89.7% women achieved reduction in pain score to ≤3 in Centchroman group (pvalue 0.001). In Danazol group 69.44% women achieved reduction in pain score to ≤ 3 (p = 0.001). Three months after stopping therapy, Centchroman was more effective in pain score reduction at 24 weeks as compared to Danazol (p = 0.019). Centchroman is an effective, safe and inexpensive alternative to Danazol for treatment of mastalgia